10 Essential Vaccine Updates for Primary Care: Winter 2024-2025
From ACIP updates on age eligibility and research on vaccine efficacy to US adults' attitudes toward recommended shots, these 10 at-a-glance news briefs are must-reads for PCPs.
Many unvaccinated adults reported intent to get vaccinated, according to early season estimates released in MMWR. Read more, here.
The FDA cleared Novavax to start enrolling the planned phase 3 trial after a safety concern was found to be unrelated to the combination vaccine. Read more, here.
Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy. Read more, here.
CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making. Read more, here.
Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said. Read more, here.
The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi. Read more, here.
Older adults hospitalized with RSV were older, more frail, and more likely to have respiratory comorbidities than those with influenza A or B, the study found. Read more, here.
Adults saying they don't need immunization this fall have received the vaccines in the past, survey authors report, suggesting a lingering misinformation effect. Read more, here.
Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data. Read more, here.
